Senior Product Owner

Sarah Cannon Research Institute to present research on Advances in blood cancers and blood disorders at 2025 ASH Annual Meeting & Exposition. December 3, 2025 | NASHVILLE, Tenn.-(BUSINESS WIRE)-Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, announced today that it will showcase its latest research through 100 abstracts and presentations at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place in Orlando, Florida and virtually from December 6-9. SCRI's expansive network is represented by more than 50 researchers who serve as first authors and co-authors across over 15 research locations. A comprehensive list of SCRI abstracts and presentations at this year's Annual Meeting & Exposition can be found here. "This year's ASH Annual Meeting & Exposition marks a milestone for SCRI, with the largest number of accepted abstracts and presentations in our history," said David Spigel, MD, Chief Scientific Officer, SCRI. "This achievement reflects not only the significance of the research, but also the meaningful collaboration and unwavering commitment of the investigators across our network, all united to advance the science that transforms care for people facing blood cancers and blood disorders." * Haydar Frangoul, MD, MS, SCRI at TriStar Centennial Children's Hospital, will present "First Results of Exagamglogene Autotemcel in Pediatric Patients Aged 5-11 Years with Transfusion-Dependent Β-Thalassemia or Sickle Cell Disease with Recurrent Severe Vaso-Occlusive Crises" in an oral presentation on Saturday, December 6 at 4:00 p.m. EST in OCCC - Chapin Theatre (W320). * Dr. Frangoul is also first author on an oral presentation titled, "Enhanced CD34+ Cell Mobilizations, Collections, and Comparable Safety Profile with Fixed Dose versus Weight-Based Plerixafor Dosing in Patients with Sickle Cell Disease Receiving Autologous CD34+ Base-Edited Hematopoietic Stem Cells in the Ongoing BEACON Study" on Monday, December 8 at 5:30 p.m. EST in Hyatt - Regency Ballroom R. * Nosha Farhadfar, MD, SCRI at Methodist Healthcare, is first author on an oral presentation alongside Stephen Strickland, MD, MSCI, SCRI, and Alireza Eghtedar, MD, SCRI at Colorado Blood Cancer Institute, titled, "Promising Results from an Ongoing Phase I Multicenter Study of Senti-202, a First-In-Class, CD33 and/or FLT3 & Not Endomucin, Selective Off-The-Shelf Logic Gated CAR NK Cell Therapy in Adults with Relapsed/Refractory Acute Myeloid Leukemia" on Monday, December 8 at 5:45 p.m. EST in OCCC - Valencia Room W415BC. * Jeff Sharman, MD, SCRI at Willamette Valley Cancer Institute & Research Center I The US Oncology Network, serves as first author alongside co-authors John Burke, MD, SCRI at Rocky Mountain Cancer Centers I The US Oncology Network, and Shachar Peles, MD, SCRI at Florida Cancer Specialists & Research Institute I The US Oncology Network, on an oral presentation titled, "Fixed Treatment Duration Subcutaneous Mosunetuzumab Monotherapy in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Interim Results from The Phase II MorningSun Study" on Saturday, December 6 at 9:45 a.m. EST in OCCC - Tangerine Ballroom F2. * Dr. Burke is first author alongside co-author Dr. Sharman on an oral presentation titled, "Fixed-Duration Subcutaneous Mosunetuzumab, with Maintenance Therapy, in Patients with Previously Untreated High-Tumor Burden Follicular Lymphoma: Longer Follow-Up and Exploratory Circulating Tumor DNA Analysis of The Phase II MorningSun Study" on Saturday, December 6 at 3:15 p.m. EST in OCCC - Tangerine Ballroom F2. * James Essell, MD, SCRI at OHC I The US Oncology Network, is first author on an oral titled, "Remote Therapeutic Monitoring Reduces Hospitalization due to Infection in Patients Being Treated for Hematological Malignancy" on Saturday, December 6 at 10:30 a.m. EST in OCCC - W230. * Dr. Farhadfar will deliver "Safety and Feasibility of 0.6 mg/kg Every 4 Weeks Dosing of Axatilimab in Patients Treated in the AGAVE-201 Study" in an oral presentation on Saturday, December 6 at 2:15 p.m. EST in OCCC - W331. In addition to scientific presentations, SCRI researchers will participate in and lead ASH Annual Meeting & Exposition sessions, including: * Hans Lee, MD, SCRI, will moderate the session, Multiple Myeloma: Pharmacologic Therapies: Advances in Treatment Strategies for Relapsed/Refractory Multiple Myeloma, on Saturday, December 6 at 2:00 p.m. EST in OCCC - West Hall D1. * Dr. Burke will present "Engagement of Community Physicians in Clinical Trials" during the session, How Can Community-Based and Academic Hematologists Foster Clinical Trial Participation as Part of Patient Care? on Sunday, December 7 at 9:40 a.m. EST in Hyatt - Plaza Int'l HIJK.

Bristol Myers Squibb expands its Strategic Collaboration with Sarah Cannon Research Institute. Bristol Myers Squibb and Sarah Cannon Research Institute expanded their strategic collaboration, leveraging SCRI's Accelero model to streamline operations, embed studies within community care settings, and extend cutting-edge oncology therapies to more diverse patient populations. In an effort to accelerate the overall development of innovative cancer therapies and increase access to clinical trials for patients across the U.S., Bristol Myers Squibb and Sarah Cannon Research Institute (SCRI) announced an expansion to its strategic collaboration.[1] Through this expanded collaboration effort, SCRI and Bristol Myers Squibb will increase access to Bristol Myers Squibb's therapy solutions by embedding clinical trials in community settings, and with more than 1,300 physicians engaged in research spanning across more than 20 states, SCRI's network enables broader participation in clinical trials.[1] During the early phase of the collaboration, SCRI achieved a 45% reduction in study startup timelines spanning across eight Bristol Myers Squibb clinical trials, significantly outperforming timelines observed at non-SCRI sites.[1] These capabilities are expected to be scaled across SCRI's research network, reinforcing a shared commitment to transforming clinical trial delivery, while also ensuring an increase to patient access to the latest cancer treatments and innovations.[1] Why did Bristol Myers Squibb and Sarah Cannon Research Institute expand its collaboration? According to a press release, a key factor of the collaboration is SCRI's next-generation clinical trial delivery model Accelero, which streamlines operations and accelerates trial execution spanning SCRI's expansive network of upwards of 200 locations.[1] The expanded collaboration effort aims to align Bristol Myers Squibb's pioneering oncology pipeline with SCRI's research infrastructure and expertise, bringing cutting-edge research directly to patients where they live and receive care.[1] "Together, SCRI and Bristol Myers Squibb are translating innovative science into clinical trials and accelerating patient enrollment through SCRI's Accelero model that prioritizes speed, quality, and access, and ultimately brings promising therapies to patients faster and closer to home," said Dee Anna Smith, chief executive officer, SCRI. "We look forward to the impact we will have together as we reach more patients and continue to redefine how clinical trials are delivered across the country." Bristol Myers Squibb's statement on its expanded collaboration with SCRI. "At Bristol Myers Squibb, we recognize that accelerating clinical trial enrollment requires not only scientific innovation but also operational innovation. This includes a deep commitment to equity and inclusion, while we look to accelerate overall patient enrollment," said Mokash Sharma, Senior Vice President, Global Development Operations, Bristol Myers Squibb. "Improving access to clinical research isn't just about science - it's about trust, and meeting people where they are. By leveraging data-driven strategies through our collaboration with Sarah Cannon Research Institute, we're working to ensure that more patients - especially those from medically underserved populations - have access to vital cancer research advances in their communities. This partnership reflects our shared vision to transform clinical trial delivery and advance health equity across the oncology landscape." * Sarah Cannon Research Institute and Bristol Myers Squibb Expand Strategic Collaboration to Accelerate Patient Enrollment and Broaden Access to Innovative Cancer Research Bristol Myers Squibb November 12, 2025 Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.